home / stock / jazz / jazz news


JAZZ News and Press, Jazz Pharmaceuticals plc From 07/03/24

Stock Information

Company Name: Jazz Pharmaceuticals plc
Stock Symbol: JAZZ
Market: NASDAQ
Website: jazzpharmaceuticals.com

Menu

JAZZ JAZZ Quote JAZZ Short JAZZ News JAZZ Articles JAZZ Message Board
Get JAZZ Alerts

News, Short Squeeze, Breakout and More Instantly...

JAZZ - US Companies Moving the Markets, Evening edition
Wed, Jul 03, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 4.6% to $128.28 on volume of 215,349,874 shares Zoomcar Holdings Inc. (ZCAR) rose 34.0% to $0.183 on volume of 204,010,215 shares Maxeon Solar Technologies Ltd. (MAXN) fell 3.5% to $0.1736 on volume of 2...

JAZZ - Baird sees Jazz study failure as positive for rival Praxis

2024-06-21 14:41:42 ET More on Praxis Precision Medicines Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing Praxis Precision Medicines announces proposed public offering Praxis gains after mid-stage data for epilepsy candidate Seeking Alph...

JAZZ - Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues

2024-06-21 09:15:24 ET Summary Jazz Pharmaceuticals plc's suvecaltamide failed in a phase 2b trial for essential tremor, but this is a minor setback for the company and one that should have been expected. The oxybate franchise is performing well despite generic Xyrem and Lumryz co...

JAZZ - Jazz Pharma slips as mid-stage trial for neuro candidate fails

2024-06-20 08:14:15 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals plc (JAZZ) Q1 2024 Earnings Call Transcript Jazz Pharmaceuticals plc 2024 Q1 - Results - Earnings Call Presentation Jazz Pharmaceuticals: Cheap But Complicated Goldman starts Jazz at buy...

JAZZ - Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor

Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor PR Newswire DUBLIN , June 20, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase ...

JAZZ - BOOM, NAD, REBN, CMG, JAZZ showing five-day upward surge

2024-06-17 10:45:03 ET DMC Global Inc (BOOM) BOOM is trading UP for the last 5 days, and it at trading at $14.55 with volume of 123,360 and a one day change of $0.12 (0.83%). DMC Global Inc has a 52-week low of 11.12 and a 52-week high of $27.16. The business's 50-day moving average...

JAZZ - Avadel Pharmaceuticals: Inflection Point Ahead

2024-06-16 10:38:06 ET Summary Avadel Pharmaceuticals is a small-cap biopharma company headquartered in Dublin, Ireland. The company's primary asset is LUMRYX, which has the potential to be a 'best of breed' compound in a large market. Currently, Avadel is locked in a pivotal ...

JAZZ -  3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition

2024-06-14 06:13:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If this year’s market volatility has left you reeling, you’re not alone. But, despite the high valuations plaguing many tech stocks , plenty of top-tier, high-quality blue-c...

JAZZ - Trend Tracker for (JAZZ)

2024-06-12 18:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

JAZZ - Goldman starts Jazz at buy, cites diversified portfolio

2024-06-05 11:34:16 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals plc (JAZZ) Q1 2024 Earnings Call Transcript Jazz Pharmaceuticals plc 2024 Q1 - Results - Earnings Call Presentation Jazz Pharmaceuticals: Cheap But Complicated Jazz presents additional p...

Previous 10 Next 10